Sysmex Life Science’s Post

More precision for better decision

Profiling HER2-enriched extracellular vesicles in breast cancer: in their latest work, Nan Jiang, Tijana Jovanovic-Talisman at City of Hope and collaborators refined the isolation process for HER2-enriched EVs from trastuzumab-sensitive and -resistant cell lines, as well as from patient plasma, using their proprietary Single Extracellular Vesicle Nanoscopy (SEVEN) technology https://lnkd.in/eHeiVCKw They found that in breast cancer patients with elevated HER2 protein expression, HER2-enriched EVs exhibited distinct characteristics, such as a higher number of tetraspanin molecules and a larger size compared to controls. An article co-authored by Andras Saftics, Ph.D., Eugenia Romano, Ph.D., Ima Ghaeli, Cristal Resto, Vanessa Robles, Saumya Das, Kendall Van Keuren-Jensen and Victoria Seewaldt #extracelllularvesicles #exosomes #breastcancer #SMLM #Vesiculab

A new allogeneic CAR-T cell platform that maintains T-cell stemness, has a more favorable cytokine profile, and demonstrates durable efficacy compared to CAR-T cells derived from adult peripheral blood mononuclear cells (PBMCs). Celularity's data, published in the Journal for ImmunoTherapy of Cancer, highlights the advantages of using placental circulating T cells for CAR-T therapy. The study found that placental T cells exhibit greater persistence, resistance to exhaustion, and efficacy compared to peripheral blood mononuclear cells. https://lnkd.in/gdMPrPaR

Check out Brimstalt Therapeutic’s preprint manuscript titled “FIS103, a Novel SULT1A1-dependent Prodrug, Demonstrates Potent Antitumor Activity in Renal Cell Carcinoma”! Brimstalt, a Fannin-established company, is developing small molecule prodrugs that are converted into potent anti-cancer agents by specific tumor associated enzymes in cancer cells, such as SULT1A1. This is a precision medicine strategy that has the potential to improve survival as well as quality of life of RCC patients and its application could be extended to other SULT1A1 expressing cancers. https://lnkd.in/gNh6WAY2 #Fannin #Brimstalt #Manuscript #PrecisionMedicine #Innovation

The “abscopal effect” is defined as regression of distant nontreated sites following primary irradiation of a specific site. The “adscopal effect," as defined by Anthony Conley et al. in a just-published editorial from the journal, Molecular Cancer Therapeutics, refers to systemic, immune-mediated shrinkage of untreated tumors after local injection with the oncolytic adenovirus, AdAPT-001, which expresses a TGF-β trap at high levels. Read here: bit.ly/3vZx0B7

Discover the groundbreaking potential of HER2-CD3-Fc bispecific antibody-encoding mRNA delivered by lipid nanoparticles in suppressing HER2-positive tumor growth. Our latest publication highlights the robust expression and potent T cell cytotoxicity induced by HER2-CD3-Fc mRNA-LNPs, demonstrating a promising therapeutic approach for treating HER2-positive cancer. Learn more about this innovative therapy by reading our full study here: https://hubs.li/Q02KrwZJ0

A new approach to tumor-informed molecular residual disease (MRD) monitoring emerges, which may detect the return of NSCLC months earlier than using a tumor-agnostic approach and help guide post-operative treatment decisions. In this recent paper, researchers working in the rapidly developing field of MRD describe the development and validation of a new method, called PROPHET, for early detection of recurrence of non-small cell lung cancer (NSCLC). Seraseq® MRD reference materials were used to help with the technical validation of the assay. Dive deeper into the study today by clicking below. https://hubs.ly/Q02hCGkz0 #NGS #Serseq #MRD

🔬 New Research Alert! published in #DrugDevIndPharm. 🌟 " Doxorubicin-sanguinarine nanoparticles: formulation and evaluation of breast cancer cell apoptosis and cell cycle " 🌟 This research article focuses on the development and characterization of san-pectinate composite nanoparticles for targeting colon cancer. The study includes the preparation of stable nano-emulsion solutions with a size diameter of 156 ± 72.11 nm and a PDI value of 0.145. The nanoparticles exhibit an irregular cubic shape and have a zeta potential of -37.6 ± 5.9 mv. The UV-VIS spectra of the nanoparticles show a significant red-shift in visible-region electromagnetic absorption. 📖 Read the full article here: https://lnkd.in/gE6x4tbu #DrugDevelopment #BreastCancerResearch #Nanoparticles #mammaryCell

Join us for a new webinar on September 25th with Dr Priti Hedge, Kite Pharma and Dr Andrew Allen, Gritstone bio. Attendees will learn: - A primer on neoantigen-directed immunotherapy, and the differentiators between the players in the field - What goes into the regulatory strategy, engineering strategy, etc for a potential first-in-class platform, in a randomized, proof-of-concept trial - Initial learnings Gritstone’s randomized Phase II trial for metastatic, microsatellite-stable colorectal cancer, and the use of circulating tumor DNA (ctDNA) in the study Learn more and register here: https://lnkd.in/e7-bx-We #immunooncology #neoantigen #IO360

💬We share the #Article "Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center “Real-World” Experience" 👥by Caroline Burgard et al. Access the full paper here👉 https://lnkd.in/dnAdYdUz Keywords: prostate cancer; biochemical recurrence; low serum prostate-specific antigen (PSA) concentration